Simmons & Simmons advises Eisai Co., Ltd. on the sale to H.A.C.

The laboratory has sold to H.A.C Pharma the European and UK rights to TARGRETIN®, a specialized hematology product.

The Paris office of the international law firm Simmons & Simmons LLP has advised Eisai Co., Ltd., a leading Japanese pharmaceutical and innovation company, on the sale to H.A.C. Pharma of the European and UK rights to TARGRETIN®, a haematology specialty product with bexarotene as its active ingredient.

The Simmons team advising Eisai Co., Ltd. was led by Paris corporate partner Christian Taylor with the support of Anna Velitchkova, Of Counsel, as well as corporate associates Laurène Salmon and Domitille Cabaud. The full team comprised:

  • Linda Zeman, Counsel, on the UK corporate aspects;

  • Anne-Catherine Perroy, Of Counsel, and Pierre-Alexis Maingon, Managing Associate, on the French pharmaceutical regulatory aspects;

  • Lydia Torne, Partner, on the UK pharmaceutical regulatory aspects;

  • Frédérique Potin, Of Counsel, on the intellectual property aspects; and

  • Emilie-Danglades-Pérez, Managing Associate, on the data protection aspects.

H.A.C. Pharma was advised by the Paris office of Dentons.